Boule Diagnostics streamlines production

The Boule Diagnostics Group is implementing a cost-reduction in instrument manufacturing, which is expected to provide an annual cost-saving of approximately SEK 3 million, beginning in the first quarter of 2019. The cost reduction is achieved through an updated design of the instruments’ electronics module that reduces the size of the module, simplifies assembly and enables faster programming. In addition, lead times can be shortened, and logistics simplified, through the choice of the new supplier, Inission. Development and prototype production of the electronics module will take place in Sweden and cost-effective, high-volume manufacturing in Estonia.

For further information, please contact:
Fredrik Dalborg, CEO and President, Boule Diagnostics AB, phone +46 70-558 51 05
Christina Rubenhag, CFO Boule Diagnostics AB, phone +46 70-546 72 22

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA and Mexico. The company’s products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. 

The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on September 21, 2018.


  • Subscribe to our news